All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
Known as:
Poly ADP Ribose Polymerase Inhibitors
, Poly (ADP-Ribose) Polymerase Inhibitors
, Poly ADP-Ribose Polymerase Inhibitors
Â
(More)
Â
National Institutes of Health
Topic mentions per year
Topic mentions per year
2010-2017
0
2
4
6
2010
2017
Related topics
Related topics
4 relations
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
Poly(ADP-ribose) Polymerase Inhibitors
olaparib
rucaparib
Related mentions per year
Related mentions per year
1986-2018
1980
1990
2000
2010
2020
Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
Poly(ADP-ribose) Polymerase Inhibitors
olaparib
rucaparib
Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Chaoyang Sun
,
Jun Yin
,
+17 authors
Gordon B. Mills
Cancer cell
2018
Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD…Â
(More)
Is this relevant?
2017
2017
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Hitomi Okuma
,
Kan Yonemori
Advances in experimental medicine and biology
2017
Breast cancer is the most common cancer in women worldwide. Treatment is chosen according to its hormone receptor status and…Â
(More)
Is this relevant?
2017
2017
PARP Inhibitors in Ovarian Cancer
Jeanine Staples
,
Annekathryn Goodman
2017
Â
Is this relevant?
2017
2017
Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.
Saswati N. Chand
,
Mahsa Zarei
,
+15 authors
Jonathan R. Brody
Cancer research
2017
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth…Â
(More)
Is this relevant?
2016
2016
PARP Inhibitors in Ovarian Cancer Treatment.
David R. Spriggs
,
Dan L. Longo
The New England journal of medicine
2016
Â
Is this relevant?
Review
2016
Review
2016
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Eileen E. Parkes
,
Richard D. Kennedy
The oncologist
2016
UNLABELLED : High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying…Â
(More)
Is this relevant?
Review
2016
Review
2016
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Angiolo Gadducci
,
Maria Elena Guerrieri
Anticancer research
2016
Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair pathways. The proteins encoded by…Â
(More)
Is this relevant?
Review
2015
Review
2015
Embracing synthetic lethality of novel anticancer therapies.
Ahmed Kamal
,
Thokhir Basha Shaik
,
Mohammed Shaheer Malik
Expert opinion on drug discovery
2015
INTRODUCTION The significant challenge posed by cancer to human healthcare has led to the exploration of new approaches to combat…Â
(More)
Is this relevant?
2014
2014
Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
Kimiyo N. Yamamoto
,
Kouji Hirota
,
Shunichi Takeda
,
Hiroshi Haeno
PloS one
2014
Platinum drugs and PARP inhibitors ("PARPis") are considered to be effective in BRCA-associated cancers with impaired DNA repair…Â
(More)
Is this relevant?
2014
2014
Models and Technologies Effect of Small-Molecule Modification on Single-Cell Pharmacokinetics of PARP Inhibitors
Greg M Thurber
,
Thomas Reiner
,
Katherine S Yang
,
Rainer H Kohler
,
Ralph Weissleder
2014
The heterogeneous delivery of drugs in tumors is an established process contributing to variability in treatment outcome. Despite…Â
(More)
Is this relevant?